Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Payables (2016 - 2026)

Lexaria Bioscience's Payables history spans 12 years, with the latest figure at $182611.0 for Q1 2026.

  • Quarterly results put Payables at $182611.0 for Q1 2026, down 89.82% from a year ago — trailing twelve months through Feb 2026 was $182611.0 (down 89.82% YoY), and the annual figure for FY2025 was $1.5 million, up 37.19%.
  • Payables for Q1 2026 was $182611.0 at Lexaria Bioscience, down from $1.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.8 million in Q1 2025 to a low of $55318.0 in Q1 2024.
  • The 5-year median for Payables is $239941.0 (2023), against an average of $591837.0.
  • The sharpest move saw Payables soared 3141.4% in 2025, then tumbled 89.82% in 2026.
  • Year by year, Payables stood at $241891.0 in 2022, then crashed by 59.09% to $98969.0 in 2023, then soared by 171.79% to $268986.0 in 2024, then surged by 429.93% to $1.4 million in 2025, then crashed by 87.19% to $182611.0 in 2026.
  • According to Business Quant data, Payables over the past three periods came in at $182611.0, $1.4 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.